Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418023 | 0.81 | CYP2D6 (0.43) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL3415521 | 0.80 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL3421216 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL3419666 | 0.75 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL7918964 | 0.75 | HSPA5 (0.50) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL3416016 | 0.74 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL20757319 | 0.73 | TRPA1 (0.32) | — | |
| SCHEMBL9356115 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL9328276 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1CA2POLBTYR | |
| SCHEMBL9330473 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1CA2POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2597114-B1 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | HITACHI LTD (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9090796-B2 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | HITACHI, LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| EP-2597114-A1 | Organic-inorganic composite materials containing triazine rings and electrical devices using the same | Hitachi Ltd. (JP) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131248-A1 | ORGANIC-INORGANIC COMPOSITE MATERIALS CONTAINING TRIAZINE RINGS AND ELECTRICAL DEVICES USING THE SAME | HITACHI, LTD. (JP) | 2013-05-23 | — | — | US | disclosed |
| US-7767739-B2 | Cyanato group-containing cyclic phosphazene compound and method for producing the same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | FUSHIMI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-6225492-B1 | CONTACTING CYANATE CRUDE PRODUCT SOLUTION COMPRISING CYANATE, UNSUBSTITUTED PHENOL AND NON-ALCOHOLIC SOLVENT WITH POOR SOLVENT CONTAINING ALCOHOL AND WATER TO CRYSTALLIZE OR PRECIPITATE SAID CYANATE | SUMITOMO CHEMICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170983-A1 | Cyanato Group-Containing Cyclic Phosphazene Compound and Method for Producing The Same | CENPE, CPNE4, MCM3 | SMN1; SMN2 1468/4885ALDH1A1 4254/4885CA2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.